Raised ~ $2M Investment to date via the University of Minnesota foundational grants and philanthropy towards the development of this Checkpoint Inhibitor
Our CD200 work has been informed by the two vaccine base clinical trials of GBM-6 for various types of brain cancers (total of 14 patients)
In all cases of the prevalence of CD200 was significant and failure was the result
Since then we have:
Demonstrated efficacy: Our human peptides demonstrated efficacy in human immune cells
Demonstrated efficacy: In this canine trial, twenty-one dogs with spontaneously occurring glioblastoma were treated with tumor resection and vaccinations consisting of canine CD200 activation receptor ligand + autologous tumor lysate. Tumor progression and overall survival were compared to historical data from a previous cohort of dogs treated with autologous tumor lysate alone after tumor resection. The extent of resection for these two cohorts was comparable. We observed a twenty-five-month progression-free survival rate of 67% in dogs that received the canine CD200AR-L. Death was due to tumor recurrence in 33% (7/21) of the dogs and 33% (7/21) of the dogs died or were euthanized for causes other than tumor progression. Two dogs without post-mortem examination were presumed to have died from tumor progression. In contrast, tumor progression was the cause of death in 100% of the dogs in the group treated with tumor lysate alone. The median survival of dogs treated with canine ligand administration with autologous tumor-lysate inoculation was 12.7 months. This survival compared favorably to the 6.36-month survival of dogs treated with tumor-lysate vaccination alone. One dog with tumor recurrence 18 months (548 days) after surgery was treated by a second surgery and autologous tumor lysate vaccine co-administered with the canine CD200AR-L and lived for an additional 9.93 months for a total of 28 months. This dog was not included in statistics.
OX2 Therapeutics has raised $2M in Series A
The funds from the Series A raise will be used to:
Initiate Phase I clinical trial enrolling 18 adults and 18 pediatrics with CNS tumors estimated start date winter of 2018-spring 2019
When the above work is completed a significant positive inflection in the overall valuation of OX2 will occur!
OX2 Development Timeline
OX2’s Management team
Michael Olin, PhD Chief Scientific Officer & Founder
Nine years of Translational Research
15 Years of Industry Experience
Jeff Liter, M.B.A. Interim CEO/Chief Financial Officer
C-Suite Executive who has profitably tripled revenues for six separate companies
COO of Progenitor Cell Therapy
CEO B-MoGen Biotech
Chris Moertel, MD Chief Medical Officer & Founder
Dahlberg Professor in the University of Minnesota
25 Years experience as neuro-oncologist driving several clinical trials
Sumant Dhawan, BS VP of Operations & Founder
CEO Cell Technology
25+ Years of Antibodies & Peptide Development
OX2’s Investigation Team
Dr. Michael Olin, PhD, inventor and co-founder of OX2 Therapeutics. Dr. Olin is an Assistant Professor in the Division of Pediatric Hematology and Oncology at the University of Minnesota. After completing his PhD in Infectious Diseases, he did two postdoctoral fellowships, studying the effects of opioids on tuberculosis meningitis and brain tumor immunotherapy and has more than 9 years experience in translational research with two other therapies that are in clinical trials.
Dr. Christopher L. Moertel, MD, co-founder of OX2 Therapeutics. Dr. Moertel is an Professor in the Division of Pediatric Hematology and Oncology and holder of the Dahlberg Professorship of Pediatric Brain Tumor Research in the University of Minnesota Medical School. Dr. Moertel has over 25 years of experience as a neuro-oncologist, directing numerous clinical trials, has served on numerous national and local professional committees and is the author of a number of book chapters, articles and abstracts. Special interests include rare pediatric tumors, neurofibromatosis-associated neoplasia, and the therapy of children with brain and spinal cord tumors.
Dr. Thomas Molitor, PhD.,Dr. Molitor is a leader in immunology and virology. Dr. Molitor received his BA in Biology/chemistry followed with a masters and PhD in Microbiology, and a Postdoctoral position in Virology at Yale. He has received funding from various agencies including NIH since his first USDA grant in 1983. His research training is in virology and immunology and maintains a laboratory at the College of Veterinary Medicine using animal model systems and cell systems. He have extensively investigated various aspects of the host response process, including macrophage and T cell effector activities. In addition we have examined the maternal effects on development of the neonatal immune response. His lab has published extensively (earlier) on diagnostic methods for virus detection. Dr. Molitor is the director of the NIH T32 training program for the past 19 years and trained 17 postdoctoral and visiting fellows, 18 doctoral students and 5 Master’s students to completion of degrees and served on the graduate committees of approximately 100 additional doctoral students. In addition, he is the director of the NIH R25 summer research program. The goal of the R25 summer program is to provide high quality research experience along with skills and educational techniques that necessary to apply for graduate or professional schools to those underrepresented students of diversity. In addition to research, he has had major administrative positions over the past 8 years as department chair of a 72 faculty clinical and research department. This position affords me the opportunity to help lead the development of faculty as future scientist and clinicians.
Dr. G. Elizabeth Pluhar, D.V.M., PhD, Member, OX2 Therapeutics Scientific Advisory Board. Dr. Pluhar is a veterinary neurosurgeon and Associate Professor in the Department of Veterinary Clinical Services at the University of Minnesota. Dr. Pluhar has collaborated with Dr. Olin for more than 6 years in the development of novel immunotherapies for canines with CNS tumors and conditions affecting the brain, spinal cord, peripheral nerves and supporting structures in canines. Together, Drs. Olin and Pluhar are successfully testing the safety and efficacy of the OX2 inhibitor in a canine high-grade brain tumor clinical trial.